Roche grants Epigenomics full rights to Tamoxifen treatment test

By Lisa Kerner

Erie, Pa., Jan. 30 - Epigenomics AG said that Roche Diagnostics will return full rights for a Tamoxifen treatment response and breast cancer molecular classification test to Epigenomics.

The tissue-based test was designed to predict the probability of disease recurrence in breast cancer patients, according to a company news release. Epigenomics will undertake sole development of the test.

The test was part of a multi-product collaboration with Roche Diagnostics. Epigenomics and Roche Diagnostics will continue to collaborate on the development of three additional screening products for colon, prostate and breast cancers.

"Now that we have sole rights to both breast and the prostate cancer molecular classification tests, which are highly synergistic in product development as they are partly based on the same biomarkers, we have two products that spearhead this strategy and form a solid basis for our own development pipeline," Epigenomics chief executive officer Alex Olek said in the release.

Epigenomics is a molecular diagnostics company focused on the development of novel products for cancer. The company has its headquarters in Berlin, Germany.

Based in Basel, Switzerland, Roche is a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.